Covid-19 vaccine developer BioNTech attracts Temasek investment

GLOBALCAPITAL INTERNATIONAL LIMITED, a company

incorporated in England and Wales (company number 15236213),

having its registered office at 4 Bouverie Street, London, UK, EC4Y 8AX

Accessibility | Terms of Use | Privacy Policy | Modern Slavery Statement | Event Participant Terms & Conditions

Cookies Settings
Equity
Equity-Linked

Covid-19 vaccine developer BioNTech attracts Temasek investment

Aidan Gregory
June 29, 2020 01:00 PM
BioNTech_Covid-19_vaccine-PA_575_575
19 June 2020, Baden-Wuerttemberg, Tübingen: ILLUSTRATION - A man demonstrates how a woman is vaccinated in the Institute for Tropical Medicine at the University Hospital of Tübingen. Today, the Institute of Tropical Medicine gave the first test person, a young woman, an injection of a potential active substance against the corona virus. The active substance comes from the Tübingen-based company Curevac. Photo: Christoph Schmidt/dpa | Christoph Schmidt/DPA/PA Images

German biotechnology company BioNTech has raised $225m via a private placement led by Singaporean sovereign wealth fund Temasek, amid growing investor appetite for biotech investments due to the Covid-19 pandemic.

Unlock this article.

The content you are trying to view is exclusive to our subscribers.

To unlock this article:

Request a Free Trial or Login

Topics

GermanyHealth and BiotechEquityUnited StatesAmericasEuropeNorth AmericaEMEASRIEquity-Linked
AG
Aidan Gregory
Gift this article